Bioventix PLC (LON:BVXP - Get Free Report)'s share price hit a new 52-week low on Wednesday . The stock traded as low as GBX 2,704 ($34.02) and last traded at GBX 2,850 ($35.85), with a volume of 12438 shares. The stock had previously closed at GBX 2,900 ($36.48).
Bioventix Trading Up 2.7 %
The firm has a market capitalization of £151.85 million, a P/E ratio of 18.76 and a beta of 0.35. The company has a 50-day moving average of GBX 3,201.58 and a 200-day moving average of GBX 3,677.77.
Insider Buying and Selling
In other news, insider Bruce Hiscock acquired 24 shares of the firm's stock in a transaction dated Friday, November 22nd. The stock was bought at an average cost of GBX 3,822 ($48.08) per share, for a total transaction of £917.28 ($1,153.96). 8.02% of the stock is owned by insiders.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Recommended Stories
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
